Showing 1 - 14 results of 14 for search '"КЛИНИЧЕСКИЙ ПРИМЕР"', query time: 0.56s Refine Results
  1. 1
    Academic Journal

    Source: Сборник статей

    File Description: application/pdf

    Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; http://elib.usma.ru/handle/usma/14316

  2. 2
    Academic Journal

    Source: Сборник статей

    File Description: application/pdf

    Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; http://elib.usma.ru/handle/usma/14333

  3. 3
    Academic Journal

    Source: Сборник статей

    File Description: application/pdf

    Relation: Актуальные вопросы современной медицинской науки и здравоохранения: сборник статей VIII Международной научно-практической конференции молодых учёных и студентов, Екатеринбург, 19-20 апреля 2023 г.; http://elib.usma.ru/handle/usma/14319

  4. 4
    Academic Journal

    Source: Aterotromboz = Atherothrombosis; № 2 (2021); 76-86 ; Атеротромбоз; № 2 (2021); 76-86 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2021-2

    File Description: application/pdf

    Relation: https://www.aterotromboz.ru/jour/article/view/257/279; Liew A., O’Donnell M., Douketis J. Comparing mortality in patients with atrial fibrillation who are receiving a directacting oral anticoagulant or warfarin: a meta-analysis of randomized trials. J Thromb Haemost. 2014;12(9):1419– 1424. https://doi.org/10.1111/jth.12651.; Ruff C.T., Giugliano R.P., Braunwald E., Hoffman E.B., Deenadayalu N., Ezekowitz M.D. et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. https://doi.org/10.1016/S0140-6736(13)62343-0.; Wu C., Alotaibi G.S., Alsaleh K., Sean McMurtry M. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review. Thromb Res. 2014;134(3):627–632. https://doi.org/10.1016/j.thromres.2014.07.001.; Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561.; Аракелян М.Г., Бокерия Л.А., Васильева Е.Ю., Голицын С.П., Голухова Е.З., Горев М.В. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. https://doi.org/10.15829/1560-4071-2021-4594.; Печерина Т.Б., Ларионов М.В., Хан Д.С., Шпагина Л.А., Пудов Е.В., Барбараш О.Л. Опыт применения в России идаруцизумаба – специфического антагониста дабигатрана. Медицинский алфавит. 2020;1(19):29–38. https://doi.org/10.33667/2078-5631-2020-19-29-38.; Huisman M.V., Fanikos J. Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. Am J Emerg Med. 2016;34(11S):46–51. https://doi.org/10.1016/j.ajem.2016.09.053.; Pollack C.V. Jr, Bernstein R., Dubiel R., Reilly P., Gruenenfelder F., Huisman M.V. et al. Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. J Med Econ. 2017;20(5):435–442. https://doi.org/10.1080/13696998.2016.1273229.; Papachristos I.V., Giannoudis P.V. Proximal femur fractures in patients taking anticoagulants. EFORT Open Rev. 2020;5(10):699–706. https://doi.org/10.1302/2058-5241.5.190071.; You D., Xu Y., Ponich B., Ronksley P., Skeith L., Korley R. et al. Effect of oral anticoagulant use on surgical delay and mortality in hip fracture. Bone Joint J. 2021;103-B(2):222–233. https://doi.org/10.1302/0301-620X.103B2.BJJ-2020-0583.R2.; Fanikos J., Murwin D., Gruenenfelder F., Tartakovsky I., França L.R., Reilly P.A. et al. Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. Thromb Haemost. 2020;120(1):27–35. https://doi.org/10.1055/s-0039-1695771.; Levy J.H., van Ryn J., Sellke F.W., Reilly P.A., Elsaesser A., Glund S. et al. Dabigatran Reversal with Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study. Ann Surg. 2021;274(3):e204-e211. https://doi.org/10.1097/SLA.0000000000003638.; Рыбачков В.В., Кабанов Е.Н., Тевяшов А.В., Абакшин Н.С. О хирургической тактике при ущемленных грыжах. Хирургия. Журнал им. Н.И. Пирогова. 2011;(12):55–58. Режим доступа: https://www.mediasphera.ru/issues/khirurgiya-zhurnal-im-n-i-pirogova/2011/12/downloads/ru/030023-120720111211.; Fauchier L., Potpara T. Idarucizumab for Reversion of Anticoagulant Effect in Daily Practice. Thromb Haemost. 2020;120(1):5–7. https://doi.org/10.1055/s-0039-1696646.; Pikija S., Sztriha L.K., Sebastian Mutzenbach J., Golaszewski S.M., Sellner J. Idarucizumab in Dabigatran-Treated Patients with Acute Ischemic Stroke Receiving Alteplase: A Systematic Review of the Available Evidence. CNS Drugs. 2017;31(9):747–757. https://doi.org/10.1007/s40263-017-0460-x.; Kermer P., Eschenfelder C.C., Diener H.C., Grond M., Abdalla Y., Althaus K. et al. Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany – A national case collection. Int J Stroke. 2017;12(4):383–391. https://doi.org/10.1177/1747493017701944.; Šaňák D., Jakubíček S., Černík D., Herzig R., Kunáš Z., Mikulík R. et al. Intravenous Thrombolysis in Patients with Acute Ischemic Stroke after a Reversal of Dabigatran Anticoagulation with Idarucizumab: A RealWorld Clinical Experience. J Stroke Cerebrovasc Dis. 2018;27(9):2479–2483. https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.05.004.; Glund S., Moschetti V., Norris S., Stangier J., Schmohl M., van Ryn J. et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113(5):943–951. https://doi.org/10.1160/TH14-12-1080.; Pollack C.V. Jr, Reilly P.A., van Ryn J., Eikelboom J.W., Glund S., Bernstein R.A. et al. Idarucizumab for Dabigatran Reversal – Full Cohort Analysis. N Engl J Med. 2017;377(5):431–441. https://doi.org/10.1056/NEJMoa1707278.; Sarode R., Milling T.J. Jr, Refaai M.A., Mangione A., Schneider A., Durn B.L., Goldstein J.N. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–1243. https://doi.org/10.1161/CIRCULATIONAHA.113.002283.; Goldstein J.N., Refaai M.A., Milling T.J. Jr, Lewis B., Goldberg-Alberts R., Hug B.A., Sarode R. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet. 2015;385(9982):2077–2087. https://doi.org/10.1016/S0140-6736(14)61685-8.; Steiner T., Poli S., Griebe M., Hüsing J., Hajda J., Freiberger A. et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol. 2016;15(6):566–573. https://doi.org/10.1016/S1474-4422(16)00110-1.; https://www.aterotromboz.ru/jour/article/view/257

  5. 5
    Academic Journal

    Source: Сборник статей

    File Description: application/pdf

    Relation: Актуальные вопросы современной медицинской науки и здравоохранения: Материалы VI Международной научно-практической конференции молодых учёных и студентов, посвященной году науки и технологий, (Екатеринбург, 8-9 апреля 2021): в 3-х т.; http://elib.usma.ru/handle/usma/5405

  6. 6
    Academic Journal

    Source: Meditsinskiy sovet = Medical Council; № 10 (2020); 101-107 ; Медицинский Совет; № 10 (2020); 101-107 ; 2658-5790 ; 2079-701X

    File Description: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/5727/5225; Омельяновский В.В. Социально­экономическое бремя бронхиальной астмы и хронической обструктивной болезни легких в Российской Федерации. Отчет по исследованию за 2008–2009 годы. М.; 2010. 63 c.; Chuchalin A.G., Khaltaev N., Аntonov N., Galkin D., Manakov L., Antonini P. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J COPD. 2014;9(1):963–974. doi:10.2147/COPD.S67283.; Karin C., Pijnenburg M., Lodrup C. Bronchial asthma. ERS Handbook: Paediatric Respiratory Medicine. European Respiratory Review. 2015;24(136):178–186. doi:10.1183/16000617.00003714.; Global Initiative for Asthma. Pocket guide for asthma management and prevention 2020. GINA website. Available at: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-full-report_-final-_wms.pdf.; Bousqet J., Mantzouranis E., Cruz A.A., Aït-Khaled N., Baena-Cagnani C.E., Bleeckeret E.R. et al. Uniform definition of asthma severity, control and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol. 2010;126(5):926–938. doi:10.1016/j.jaci.2010.07.019.; Chung K.F., Wenzel S.E., Brozek J.L., Bush A., Castro M., Sterk P.J. et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal. 2014;43(2):343–373. doi:10.1183/09031936.00202013.; Porsbjerg C., Menzies-Gow A. Co-morbidities in severe asthma Clinical impact and management. Respirology. 2017;22(4):651–661. doi:10.1111/resp.13026.; Partridge M.R., van der Molen T., Myrseth S.E., Busse W.W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. doi:10.1186/1471-2466-6-13.; Архипов В.В., Григорьева Е.В., Гавришина Е.В. Контроль над бронхиальной астмой в России: результаты многоцентрового наблюдательного исследования НИКА. Пульмонология. 2011;(6):87–93. doi:10.18093/08690189-2011-0-6-87-93.; Djukanovic R., Wilson J.W., Britten K.M., Wilson S.J., Walls A.F., Roche W.R. et al. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis. 1992;145(3):669–674. doi:10.1164/ajrccm/145.3.669.; Авдеев С.Н., Айсанов З.Р., Архипов В.В., Белевский А.С., Визель А.А., Демко И.В. и др. Принципы выбора терапии для больных легкой астмой. Согласованные рекомендации РААКИ и РРО. Российский аллергологический журнал. 2017;14(3):41–50. Режим доступа: https://rusalljournal.ru/raj/article/view/313.; Gandhi N.A., Bennett B.L., Graham N.M., Pirozzi G., Stahl N., Yancopoulos G.D. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi:10.1038/nrd4624.; Курбачева О.М., Галицкая М.А. Место антилейкотриеновых препаратов в противовоспалительной терапии бронхиальной астмы. Российский аллергологический журнал. 2017;14(4–5):71–78. Режим доступа: https://rusalljournal.ru/raj/article/view/298.; Greenberger P.A. Lessons Learned From Clinical Trials of Asthma. Allergy Asthma Proc. 2019;40(6):410–413. doi:10.2500/aap.2019.40.4259.; Barnes P.J. Tiotropium bromide. Expert Opin Investig Drugs. 2001;10(4):733–740. doi:10.1517/13543784.10.4.733.; Meng J.F., Li H., Luo M.J., Li H.B. Efficacy of tiotropium in treating patients with moderate-to-severe asthma: A meta-analysis and systematic review based on 14 randomized controlled trials. Medicine (Baltimore). 2019;98(33):e16637. doi:10.1097/MD.0000000000016637.; Vogelberg C., Goldstein S., Graham L., Kaplan A., de la Hoz A., Hamelmann E. A comparison of tiotropium, long-acting β2 -agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma. Respir Res. 2020;21(1):19. doi:10.1186/s12931-0201282-9.; Murphy K.R., Chipps B.E. Tiotropium in children and adolescents with asthma. Ann Allergy Asthma Immunol. 2020;124(3):267–276. doi:10.1016/j.anai.2019.11.030.; Radovanovic D., Santus P., Blasi F., Mantero M. Erratum to: The evidence on tiotropium bromide in asthma: from the rationale to the bedside. Multidiscip Respir Med. 2017;12:17. doi:10.1186/s40248-017-0099-y.; Ohta S., Oda N., Yokoe T., Tanaka A., Yamamoto Y., Watanabe Y. et al. Effect of tiotropium bromide on airway inflammation and remodelling in a mouse model of asthma. Clin Exp Allergy. 2010;40(8):1266–1275. doi:10.1111/j.1365-2222.2010.03478.x.; Суровенко Т.Н., Глушкова Е.Ф. Новые возможности терапии бронхиальной астмы у детей. Медицинский совет. 2018;(17):192–198. doi:10.21518/2079-701X-2018-17-192-198.; Vogelberg C., Moroni-Zentgraf P., Leonaviciute-Klimantaviciene M., Sigmund R., Hamelmann E., Engel M. et al. A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids. Respir Res. 2015;16:20. doi:10.1186/s12931-015-0175-9.; Hamelmann E., Bernstein J.A., Vandewalker M., Moroni-Zentgraf P., Verri D., Unseld A., Engel M., Boner A.L. A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma. Eur Respir J. 2017;49(1):1601100. doi:10.1183/13993003.01100-2016.; Hamelmann E., Szefler S.J. Efficacy and Safety of Tiotropium in Children and Adolescents. Drugs. 2018;78(3):327–338. doi:10.1007/s40265-0180862-1.; Vogelberg C., Szefler S.J., Vrijlandt E.J.L.E., Boner A.L., Engel M., El Azzi G. et al. Tiotropium add-on therapy has a safety profile comparable with that of placebo in children and adolescents with symptomatic asthma. Eur Respir J. 2019;53(6):1801824. doi:10.1183/13993003.01824-2018.; Vrijlandt E., El Azzi G., Vandewalker M., Rupp N., Harper T., Graham L.R. et al. Safety and efficacy of tiotropium in 1–5-year-old children with persistent asthmatic symptoms: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2018;6(2):127–137. doi:10.1016/S22132600(18)30012-2.; Efficacy of Intermittent Tiotropium in Early Childhood Wheezing. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT03199976.; Kalayci O., Abdelateef H., Pozo Beltrán C.F., El-Sayed Z.A., Gómez R.M., Hossny E. et al. Challenges and choices in the pharmacological treatment of non-severe pediatric asthma: A commentary for the practicing physician. World Allergy Organ J. 2019;12(9):100054. doi:10.1016/j.waojou.2019.100054.; Ducharme F.M., Lemire C., Noya F.J. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Engl J Med. 2009;360:339–353. doi:10.1056/NEJMoa0808907.; Szefler S.J., Phillips B.R., Martinez F.D. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115(2):233–242. doi:10.1016/j.jaci.2004.11.014.; Vogelberg C., Engel M., Laki I. Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma. J Allergy Clin Immunol Pract. 2018;(6)6:2160–2162. doi:10.1016/j.jaip.2018.04.032.; Hamelmann E., Bateman E.D., Vogelberg C. Tiotropium add-on therapy in adolescents with moderate asthma: a 1-year randomized controlled trial. J Allergy Clin Immunol. 2016;138(2):441–450. doi:10.1016/j.jaci.2016.01.011.

  7. 7
  8. 8
    Academic Journal

    Source: Rational Pharmacotherapy in Cardiology; Vol 12, No 6 (2016); 698-702 ; Рациональная Фармакотерапия в Кардиологии; Vol 12, No 6 (2016); 698-702 ; 2225-3653 ; 1819-6446 ; 10.20996/1819-6446-2016-12-6

    File Description: application/pdf

    Relation: https://www.rpcardio.com/jour/article/view/1373/1406; Park S.J., Park S.W. Hong M. et al. Longterm (three year) outcomes after stenting of unprotected left main coronary artery stenosis in patients with normal left ventricular function. Am J Cardiol. 2003;91:12-6.; Chieffo A., Orlic D., Airoldi F. Early and midterm results of Cypher stents in unprotected left main. J Am Coll Cardiol. 2004;43(5):1116-8.; Barbarash O.L., Polikutina O.M., Tavlueva E.V. et al. The defeat of the main left coronary artery: view of cardiologist. Kreativnaya Kardiologiya. 2015 (2): 5-15 (In Russ.) [Барбараш О.Л., Поликутина О.М., Тавлуева Е.В. и др. Поражение ствола левой коронарной артерии: взгляд кардиолога. Креативная Кардиология. 2015;(2):5-15].; ESC/EACTS Guidelines on myocardial revascularization The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of theEuropean Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46(4):517-92.; Fajadet J., Chieffo A. Current management of left main coronary artery disease. Eur Heart J. 2012;33(1):36-50.; Jotsman M.S., Lewis B.S., Bahst A. Obstruction of the LMCA -the artery of sudden death. S Afr. Med J. 1973; 47:641-4.; Fajadet J., Chieffo A. Current management of left main coronary artery disease. Eur Heart J. 2012;33(1):36-50b.; Kuznetsov V.A., Bessonov I.S., Zyryanov I.P. et al. Clinical and functional characterization and treatment of patients with lesions of the left main coronary artery in clinical practice. Kardiologiia. 2014; 1: 5560 (In Russ.) [Кузнецов В.А., Бессонов И.С., Зырянов И.П. и др. Клинико-функциональная характеристика и лечение пациентов с поражением ствола левой коронарной артерии в реальной клинической практике. Кардиология. 2014;1:55-60].; Mohr F.W., Morice M.C., Kappetein A.P. et al. Coronary artery bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year followup of the randomised, clinical SYNTAX trial. Lancet 2013;381(9867):629-38.; Seung K.B., Park D.W., Kim Y.H. et al. Stents versus coronary-artery bypass grafting for left main coronary artery disease. N Engl J Med. 2008;358:1781-92.; Park H.S., Ahn T., Chae I.H. et al. Long-term safety and efficacy of stenting versus coronary artery bypass grafting for unprotected left main coronary artery disease: 5-year results from the MAIN-COMPARE (Revascularization for Unprotected Left Main Coronary Artery Stenosis: Comparison of Percutaneous Coronary Angioplasty Versus Surgical Revascularization) registry. J Am Coll Cardiol. 2010;56:117-24.; Chieffo A., Morici N., Maisano F. et al.: Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. Circulation. 2006;113:2542-7.; Chieffo A., Magni V., Latib A. et al. 5-year outcomes following percutaneous coronary intervention with drug-eluting stent implantation versus coronary artery bypass graft for unprotected left main coronary artery lesions the Milan experience. JACC Cardiovasc Interv. 2010;3:595-601.; https://www.rpcardio.com/jour/article/view/1373

  9. 9
    Academic Journal

    Source: Cancer Urology; Том 13, № 2 (2017); 113-120 ; Онкоурология; Том 13, № 2 (2017); 113-120 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2017-13-2

    File Description: application/pdf

    Relation: https://oncourology.abvpress.ru/oncur/article/view/655/666; Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2015 году. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2017. 250 с. [Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant tumors in Russia in 2015. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS” Minzdrava Rossii, 2017. 250 р. (In Russ.)].; World Health Organization. Skin cancers. Available at: www.who.int. (last accessed September 15, 2011).; Ferlay J., Shin H.R., Bray F. et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127(12):2893–917. DOI:10.1002/ijc.25516. PMID: 21351269.; Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Под ред. М.И. Давыдова, Е.М. Аксель. М.: Издательская группа РОНЦ, 2014. 226 с. [Statistics of malignant tumors in Russia and CIS countries in 2012. Eds.: М.I. Davydov, Е.М. Аksel’. Мoscow: Izdatel’skaya gruppa RONTS, 2014. 226 p. (In Russ.)].; Мяснянкин М.Ю., Гафтон Г.И., Анисимов В.В. и др. Акральная лентигинозная меланома: современное состояние проблемы. Вопросы онкологии 2015;61(4):563–70. [Myasnyankin M.Yu., Gafton G.I., Anisimov V.V. et al. Acral lentiginous melanoma: the current state of the problem. Voprosy onkologii = Issues of Oncology 2015;61(4):563–70. (In Russ.)].; El-Safadi S., Estel R., Mayser P., Muenstedt K. Primary malignant melanoma of the urethra: a systematic analysis of the current literature. Arch Gynecol Obstet 2014;289(5):935–43. DOI:10.1007/s00404-013-3130-3. PMID: 24370958.; Oliva E., Quinn T.R., Amin M.B. et al. Primary malignant melanoma of the urethra: a clinicopathologic analysis of 15 cases. Am J Surg Pathol 2000;24(6):785–96. PMID: 10843280.; van Geel A.N., den Bakker M.A., Kirkels W. et al. Prognosis of primary mucosal penile melanoma: a series of 19 Dutch patients and 47 patients from the literature. Urology 2007;70(1):143–7. DOI:10.1016/j.urology.2007.03.039. PMID: 17656225.; Seetharamu N., Ott P.A., Pavlick A.C. Mucosal melanomas: a case-based review of the literature. Oncologist 2010;15(7):772–81. DOI:10.1634/theoncologist.2010-0067. PMID: 20571149.; Garbe C., Peris K., Hauschild A. et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016. Eur J Cancer 2016;63:201–17. DOI:10.1016/j.ejca.2016.05.005. PMID: 27367293.; Stillwell T.J., Zincke H., Gaffey T.A., Woods J.E. Malignant melanoma of the penis. J Urol 1988;140(1):72–5. PMID: 3379702.; Papeš D., Altarac S. Melanoma of the female urethra. Med Oncol 2013;30(1):329. DOI:10.1007/s12032-012-0329-2. PMID: 23254965.; Bracken R.B., Diokno A.C. Melanoma of the penis and the urethra: 2 case reports and review of the literature. J Urol 1974;111(2):198–200. PMID: 4810764.; Oldbring J., Mikulowski P. Malignant melanoma of the penis and male urethra. Report of nine cases and review of the literature. Cancer 1987;59(3):581–7. PMID: 3791167.; Levine R.L. Urethral cancer. Cancer 1980;45(7 Suppl):1965–72. PMID: 7370946.; Sugaya K., Yataki T., Yshikawa S., Kanoh S. A case of amelanotic malignant melanoma of the female urethra. Jap J Cein Oncol 1983;13(2):435–9. PMID: 6887560.; Pow-Sang J.M., Klimberg I.W., Hackett R.L., Wajsman Z. Primary malignant melanoma of the male urethra. J Urol 1988;139(6):1304–6. PMID: 3286893.; Robert C., Schachter J., Long G.V. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;375(26):2521–32. DOI:10.1056/NEJMoa1503093. PMID: 25891173.; https://oncourology.abvpress.ru/oncur/article/view/655

  10. 10
  11. 11
  12. 12
  13. 13
  14. 14